HemodialysispatientwithchronicHCVinfection,whowasstartedonmonotherapywithinterferon.Quali-tativeHCVRNAremainedpositiveat12weeksoftreatment;ribavirinwasassociated.HCVRNAwasnega-tiveatweek24andtreatmentwasextendedto72weeks.HCVRNAnegativesixmonthsaftertreatment.
INTRODUCTION
The prevalence of hepatitis C virus (HCV) infection ranges from 1% to 3% in general population, 1 but it is higher in hemodialysis (HD)patients,rangingfrom3%to23%. 1 This differencecanberelatedtothefactthatpatients onHDhaveriskfactorsforacquisitionofHCV, suchasreceiptofbloodtransfusionsanduseof illicit intravenous drug, and may also acquire bloodborneinfectionsasaresultofhealthcareassociated transmission in HD units. Several mechanisms have been implicated in HCV transmissionamongHDpatients,suchasdialyzer reuse, contamination of hands of staff members,oritemssharedamongpatients. 1 HCVinfectionincreasesmortalityinHDpatientsandinrenaltransplantrecipients(RTR). 2, 3 Cirrhosisandhepatocellularcarcinoma(HCC), majorcomplicationsofHCV-associatedchronic liver disease, have been implicated as causes of increased mortality in HD patients with HCV infection. 2, 4 AstudyamongHDpatientsshowed thatHCCaccountedfor5.5%ofalldeathsinthe groupwithHCVinfectioncomparedwith0%in thegroupwithoutHCVinfection. 5 Inaddition, cirrhosiswasdocumentedin8.8%and0.4%of deceasedpatientswithandwithoutHCVinfection,respectively(p<0.001). 5 ReducedsurvivalinRTRswithHCVisattributabletoadvancedliverdiseaseandsepsis. 6 BothliverdiseaseandsepsisinRTRswithHCV arelikelytobedirectconsequencesofcirrhosis. Inacase-controlstudy,cirrhosiswasthemost signiicantindependentpredictorofdeathafter renaltransplantation. 7 Despitetheincreaseof liver disease and sepsis in RTRs, renal transplantation improves overall survival in non-cirrhoticpatientswithHCVinHD. 8 The presence of cirrhosis in HD patients with HCV infection is considered a relative contraindicationforrenaltransplantationdue topossibleprogressionofliverdisease. 6 Combinedtransplantation(liver/kidneytransplantation) is recommended in renal transplantationcandidateswithdecompensatecirrhosis.It is often recommended that HD patients with compensatedcirrhosiswhoseliverfunctionis too well compensated to require liver transplantationremainondialysis. 6 Because sustained HCV suppression prevents progression of liver disease and HCV therapy with interferon (IFN) is not recommended after renal transplantation, antiviral therapy should be considered for patients in HD with HCV infection prior to transplant. 6 PatientswithcompensatedhepatitisCcirrhosiswhoachievesustainedviralresponse(SVR), i.e.,negativeHCVRNAsixmonthsaftertreatment,maybecomesuitablecandidatesforisolated renal transplantation. 6 This emphasizes the potential beneit of HCV antiviral treatment.However,atpresent,therapyforhepatitis CinHDpatientsisdificult,especiallybecause of potential adverse effects of treatment and presence of comorbidities in these patients. In this report, we present a HD patient with chronic HCV infection and cirrhosis treated withIFNmonotherapyfor16weeks,andIFN plusribavirin(RBV)foradditional56weeks. Vigani,Pavan,Tozzoet al.
DISCUSSION
Thestandardtreatmentforpatientswithchronichepatitis C genotype 1 infection is pegylated interferon alfa (PEG-IFN) therapy in combination with RBV for 48 weeks and 24weeksforpatientswithgenotype3infection.Innon-HD patients,thiscombinationachievedSVRin50%to60%of patients. 1 ThereisnocurrentoptimaltherapyforhepatitisC inHDpatients.ThecombinationofPEG-IFNandRBVhas notbeenstudiedextensivelyinHDpatients,asmoststudies havefocusedonmonotherapywithIFN.Twometa-analyses reportedSVRratesof33%and37%inHDpatientstreated with IFN as monoteraphy. 10, 11 These rates are signiicantly greaterthantheSVRratesobservedinpreviouslypublished studies,10%to20%,amongnon-HDpatientstreatedwith IFNmonoteraphy. 1 Theseincreasedresponseratesmaybe partially explained by an increased half-life of IFN in HD patients,resultingingreaterplasmalevelsandconsequent increaseineficacyandalsointheincidenceofsideeffects. InHDpatients,SVRratesinthreestudiesofPEG-IFN monotherapy were similar (37%) to those for IFN monotherapy, but SVR rates increased to 97% and 44% in two studies using PEG-IFN and RBV. 1 In this report, we de-scribedapatientinHDwithHCVchronicinfectiontreated withIFN-αmonoteraphyfor16weeksandthenwithIFN-α andRBVforadditional56weeks.HCVRNAbecomenega-tiveonlyafterRBVwasinitiated.
Clinicians are usually reluctant to use RBV in HD patients because only a small part of the drug is eliminated duringHDsessionsandsideeffectsincludeadose-dependent hemolysis, which may be even more severe in chroni-callyanemicHDpatients. 12 Inaddition,alackofknowledge aboutadequateRBVdosingandpresenceofothercomorbidities(e.g.,cardiacischemia)hasfurtherdiscouragedthe useofRBVinHDpatients.However,studieshaveevaluated combinationtherapyofeitherPEG-IFNorIFN-αplusRBV inpatientsinmaintenanceHD. 13, 14 Inonestudy,SVRratein HDpatientstreatedwithIFN-αplusRBVwas83.3%,and themostfrequentsideeffectofRBVwasadose-dependent hemolysis, which required treatment discontinuation in somepatients. 14 Thisconcentration-monitoredsafetystudy indicated that it was possible to use combination therapy, IFN-α plus RBV, in HD patients. However, some precau-tionsweresuggestedforRBVuseinthissetting,including closemonitoringofHblevels,reduceddosesofRBV,start usingEPOor,inthosepatientsalreadyusingEPO,increase itsdosingeitherincreasingdosesofEPOinpatientsalready inuseoritsinitiationothers. 15 TransfusionsandRBVdiscontinuation may be necessary to manage RBV-induced anemiainsomepatients.
Inourreport,theinitialRBVdosecouldbeconsidered lowforan85kgpatient.ThestandardRBVdoseforanon-HDpatientinfectedwithgenotype1is15mg/kg,equivalent to1,200mginthispatient.Patienttoleratedtreatmentwell and did not develop RBV-induced anemia. So, it was not necessary to increase his EPO dose. The small sample size ofpreviousstudiesinHDandchronichepatitisCpatients hampersdeinitiveconclusionsaboutoptimaltherapy,but encouragingresultsintermsofeficacyandsafetyhavebeen reported. 4, 14 Randomized trials with large numbers of patientsarenecessarytoinvestigateoptimalcombinationther-apyandmanagementofsideeffectsamongHDpatients.
ThereisalackofcomprehensiveinformationonHCV-relatedcirrhosisinpatientsinHD,asstudiesarelimitedto a few case reports. Standard IFN-α monotherapy in three HD HCV-infected patients with cirrhosis showed reversibilityofcirrhosisbybiopsyintwoofthem. 16 Ourpatient hadevidenceofcirrhosisonultrasoundandwedecidednot toperformliverbiopsybeforeandafterantiviraltreatment, butSVRaftertreatmentasseeninthispatientisusuallyassociatedwithimprovedliverhistology. 17 VirologicalresponsetoHCVtreatmentinnon-HDpatientsisinfluencedbydifferenthostandvirusfactors.Host factors associated with a reduced virological response to PEG-IFNandRBVcombinationtherapyareolderage,male gender,African-Americanethnicity,elevatedBMI,advanced ibrosisorcirrhosis,andliversteatosis. 18 Themostimportantviralfactorforpredictionofvirologicalresponseisthe HCV genotype. HCV genotype 2-or 3-infected patients generally have higher SVR rates than genotype 1-infected patients.Inaddition,alowbaselineviralloadisalsoassociated with increased rates of virological response. 17 Similar tonon-HDpatients,greaterSVRrateswereobservedinHD patientswithnon-HCVgenotype1infections,withoutcirrhosisorbridgingibrosis,andlowmeanpretreatmentHCV RNAlevels. 1 Wenoticedthatourpatienthadsomefactors,suchas genotype1infection,malegender,elevatedBMI,andcirrhosis,thathavebeenshowntobepredictorsofdecreased response to IFN-α and RBV therapy. 18 For non-HD patients,aslowvirologicalresponsetoHCVtreatmentcanbe deinedaspatientswhobecomeHCVRNAnegativeonly atweek24.
Asshownbypreviousstudies,prolongationoftherapy from48to72weeksmaybenecessaryinpatientswithslow virologicalresponse. 19 Extendingcombinationtherapyfrom 48to72weeksledtoanincreaseofSVRratesfrom17%to 29%amongpatientswithdetectableHCVRNAatweek12 whobecameHCVRNAnegativeonlybyweek24. 19 Because our patient was a slow virological responder, HCV RNA negativationatweek24,wedecidedtoextendhistreatment to72weeks,andheattainedSVR.Atthepresent,nostudies evaluatingextendedHCVtherapyinHDpatientsareavailable;therefore,furtherstudiesarenecessarytodeterminethe appropriatedurationofHCVtreatmentinHDpatients.
Thereislittleinformationonoptimaltreatmentofhepa-titisCamongHDpatients.ThedecisiontoinitiateIFNand RBVtherapyinsuchpatientsshouldbebasedonhistologicalseverityofliverdisease,presenceofcomorbidities,and expected tolerance of side effects. In addition, clinicians shouldcarefullymonitorthepatientduringtreatmentand makenecessaryadjustmentstoreachdesiredoutcomesand minimize side effects. By doing so, it may be possible to achieve high rates of SVR with the already available treatmentoptions.
